文献速递肾癌与肾肿瘤

新型风险评分用于选择转移性肾细胞癌减瘤性肾切除术最佳候选患者:多机构注册研究(REMARCC)

Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC).
PubMed 文献 · Eur Urol Oncol · 2020-12-29

基于多机构REMARCC注册研究中519例同期转移性肾细胞癌行减瘤性肾切除术的患者,开发并评估了一种预测总体死亡风险的新评分系统。该模型纳入肥胖、骨/肝/肺转移、体能状态及转移灶数量等变量,C指数(66.4%)高于MSKCC(60.4%)和IMDC(60.3%)模型,并将部分按后两者分类为中/高危的患者重新归为良好预后。

要点

  • REMARCC新评分区分良好、中等、不良预后,比例分别为22.0%、39.5%、38.5%。
  • 新模型C指数66.4%优于MSKCC(60.4%)和IMDC(60.3%)评分。
  • 肥胖与较低死亡风险相关,骨/肝/肺转移及体能状态差与较高死亡风险相关。

核心结论

  • 肿瘤与患者特征对mRCC行CN的风险分层和临床决策有重要意义。
  • 新评分模型区分度优于MSKCC和IMDC,但需前瞻性外部验证。

研究设计与样本

  • 多机构注册研究(REMARCC),纳入2005—2019年519例同期mRCC行CN患者。
  • 采用Cox比例风险回归筛选总体死亡预测因子,并以C指数评价区分度。

主要发现

  • 中位随访18个月(IQR 5.9–39.7)。
  • 肥胖患者死亡率较低(p=0.007);骨转移(p=0.010)、肝转移(p=0.002)、肺转移(p<0.001)者OM更高。
  • 体能状态<80%(p=0.026)及转移灶>3个(p=0.040)者OM更高。
  • REMARCC模型C指数66.4%,高于MSKCC 60.4%和IMDC 60.3%。
  • 按REMARCC分层:良好113例(22.0%)、中等202例(39.5%)、不良197例(38.5%)。

关键数值与推荐

  • 良好预后:无风险因素;中等预后:1–2个风险因素;不良预后:>2个风险因素。
  • 按MSKCC和IMDC分别有72例(17.2%)和51例(13.9%)中/不良预后患者被REMARCC重归为良好预后。

临床怎么用

  • 可结合肿瘤负荷、转移部位、体能状态和肥胖等患者特征辅助筛选CN候选者。
  • 新评分可能纠正MSKCC/IMDC对部分患者的风险高估,但需外部验证后用于临床。

局限性

  • 随访时间较短,中位仅18个月。
  • 回顾性多机构注册数据,需前瞻性外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selection of patients for upfront cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) has to be improved. OBJECTIVE: To evaluate a new scoring system for the prediction of overall mortality (OM) in mRCC patients undergoing CN. DESIGN, SETTING, AND PARTICIPANTS: We identified a total of 519 patients with synchronous mRCC undergoing CN between 2005 and 2019 from a multi-institutional registry (Registry for Metastatic RCC [REMARCC]). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Cox proportional hazard regression was used to test the main predictors of OM. Restricted mean survival time was estimated as a measure of the average overall survival time up to 36 mo of follow-up. The concordance index (C-index) was used to determine the model's discrimination. Decision curve analyses were used to compare the net benefit from the REMARCC model with International mRCC Database Consortium (IMDC) or Memorial Sloan Kettering Cancer Center (MSKCC) risk scores. RESULTS AND LIMITATIONS: The median follow-up period was 18 mo (interquartile range: 5.9-39.7). Our models showed lower mortality rates in obese patients (p = 0.007). Higher OM rates were recorded in those with bone (p = 0.010), liver (p = 0.002), and lung metastases (p < 0.001). Those with poor performance status (<80%) and those with more than three metastases had also higher OM rates (p = 0.026 and 0.040, respectively). The C-index of the REMARCC model was higher than that of the MSKCC and IMDC models (66.4% vs 60.4% vs 60.3%). After stratification, 113 (22.0%) patients were classified to have a favorable (no risk factors), 202 (39.5%) an intermediate (one or two risk factors), and 197 (38.5%) a poor (more than two risk factors) prognosis. Moreover, 72 (17.2%) and 51 (13.9%) patients classified as having an intermediate and a poor prognosis according to MSKCC and IMDC categories, respectively, would be reclassified as having a good prognosis according to the REMARCC score. CONCLUSIONS: Our findings confirm the relevance of tumor and patient features for the risk stratification of mRCC patients and clinical decision-making regarding CN. Further prospective external validations are required for the scoring system proposed herein. PATIENT SUMMARY: Current stratification systems for selecting patients for kidney removal when metastatic disease is shown are controversial. We suggest a system that includes tumor and patient features besides the systems already in use, which are based on blood tests.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Marchioni M, Kriegmair M, Heck M, et al. Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). Eur Urol Oncol. 2020. PMID: 33384274. doi:10.1016/j.euo.2020.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。